European Radiology:MRE在评估HCC微血管侵犯中的应用

2022-04-18 shaosai MedSci原创

MR弹性成像(MRE)是一项成熟的技术,在检测和分期肝脏纤维化方面具有很高的诊断性能,同时在评估恶性肿瘤方面也有新的作用。

肝细胞癌(HCC)是全世界范围内第五大最常见的恶性肿瘤,也是与癌症相关的第二大死亡原因。肝脏切除术是目前治疗HCC最有效、常用的术式选择。然而,据报道,HCC的术后5年复发率高达70%,大大缩短生存时间。微血管侵犯(MVI)是肿瘤侵袭性的指标,是HCC患者肝切除后复发和预后不良的重要独立预测因素。因此,术前预测MVI对于决定患者的最佳临床治疗方案至关重要。然而,与大血管侵犯不同的是,大血管侵犯在术前影像中是可见的,而MVI只能通过术后组织病理进行诊断因此开发一种无创的方法来预测术前MVI的存在具有相当的临床价值。

到目前为止,许多学者通过CT或MRI的影像学特征(如肿瘤边缘、动脉边缘增强或肝胆的瘤周低信号),试图在术前影像学图像上识别MVI。然而,在评估这些影像特征时,即使是有经验的放射科医生也有很高的观察者间差异,因此导致临床实践中争议不断

MR弹性成像(MRE)是一项成熟的技术,在检测和分期肝脏纤维化方面具有很高的诊断性能,同时在评估恶性肿瘤方面也有新的作用。以前的一些MRI研究也表明,MRE可以应用于HCC患者的检测和定性、治疗反应的预测以及治疗反应的监测。最近,一项基于MRE的技术,即 "滑移界面成像"(SII),利用剪切应变图对脑部肿瘤的瘤周组织粘连程度进行了非侵入性的量化,可具有高风险的手术并发症和手术侵袭性的患者进行识别

近日,发表在European Radiology杂志的一项研究在病理证实的HCC患者中使用基于MRE的剪切应变图谱作为生物标志物肿瘤-肝脏界面的特征进行识别进一步实现术前MVI无创性评估

本研究于2016年12月至2019年10月期间,59名经组织病理学证实的HCC患者进行了常规60Hz MRE检查(+/-MVI,n = 34/25),其中一个亚组包括29/59名患者(+/-MVI,n = 16/13),同时也接受了40和30Hz MRE检查。计算八面体剪切应变(OSS)图,并记录低剪切应变的瘤周界面长度的百分比(即低剪切应变长度,pLSL,%)。对于OSS-pLSL,分别使用MVI(+)组和MVI(-)组之间的差异和不同MRE频率下的诊断性能,用Mann-Whitney检验和受试者工作特性曲线下的面积(AUC)进行分析。 

在三个频率下,MVI(+)组的瘤周OSS-pLSL明显高于MVI(-)组(均为P<0.01)。在所有的频率组中,预测MVI的瘤周OSS-pLSL的AUC是良好/优秀的(60-Hz。0.73(n = 59)/0.80(n = 29);40-Hz。0.84;30-Hz。0.90). 在进一步分析所有频率的29个病例时,AUCs没有明显差异。随着频率从60-Hz下降,OSS的特异性在40-Hz增加(53.8-61.5%),在30-Hz进一步增加(53.8-76.9%),而在较低的频率下,敏感性仍然很高(100.0-93.8%)(所有P>0.05)。 


 a 肿瘤ROI和瘤周肝实质ROI叠加MRE幅值图像。 b 肿瘤-肝实质接触的实际长度(绿线,62.37mm)。 c 高剪切应变界面(黄色箭头)和低剪切应变界面(白色箭头)的OSS图。 d 低剪切应变肿瘤-肝实质界面的实际长度(白线,8.57mm)

本研究表明,基于MRE的剪切应变图可成为评估HCC患者肿瘤-肝脏界面状态的影像学指标,并可在术前无创地预测MVI的存在。

原文出处

Mengsi Li,Ziying Yin,Bing Hu,et al.MR Elastography-Based Shear Strain Mapping for Assessment of Microvascular Invasion in Hepatocellular Carcinoma.DOI:10.1007/s00330-022-08578-w

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1649513, encodeId=929d1649513d4, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Fri Nov 18 01:25:58 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729504, encodeId=c7131e29504e1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Aug 19 10:25:58 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219750, encodeId=ea381219e505e, content=nice,学习了 , beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3e76499938, createdName=ms6000001791212108, createdTime=Sun May 15 11:20:08 CST 2022, time=2022-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259565, encodeId=1eba12595658c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sun Apr 17 01:25:58 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365436, encodeId=c8f113654365a, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sun Apr 17 01:25:58 CST 2022, time=2022-04-17, status=1, ipAttribution=)]
    2022-11-18 freve
  2. [GetPortalCommentsPageByObjectIdResponse(id=1649513, encodeId=929d1649513d4, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Fri Nov 18 01:25:58 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729504, encodeId=c7131e29504e1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Aug 19 10:25:58 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219750, encodeId=ea381219e505e, content=nice,学习了 , beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3e76499938, createdName=ms6000001791212108, createdTime=Sun May 15 11:20:08 CST 2022, time=2022-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259565, encodeId=1eba12595658c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sun Apr 17 01:25:58 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365436, encodeId=c8f113654365a, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sun Apr 17 01:25:58 CST 2022, time=2022-04-17, status=1, ipAttribution=)]
    2022-08-19 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1649513, encodeId=929d1649513d4, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Fri Nov 18 01:25:58 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729504, encodeId=c7131e29504e1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Aug 19 10:25:58 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219750, encodeId=ea381219e505e, content=nice,学习了 , beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3e76499938, createdName=ms6000001791212108, createdTime=Sun May 15 11:20:08 CST 2022, time=2022-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259565, encodeId=1eba12595658c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sun Apr 17 01:25:58 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365436, encodeId=c8f113654365a, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sun Apr 17 01:25:58 CST 2022, time=2022-04-17, status=1, ipAttribution=)]
    2022-05-15 ms6000001791212108

    nice,学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1649513, encodeId=929d1649513d4, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Fri Nov 18 01:25:58 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729504, encodeId=c7131e29504e1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Aug 19 10:25:58 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219750, encodeId=ea381219e505e, content=nice,学习了 , beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3e76499938, createdName=ms6000001791212108, createdTime=Sun May 15 11:20:08 CST 2022, time=2022-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259565, encodeId=1eba12595658c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sun Apr 17 01:25:58 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365436, encodeId=c8f113654365a, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sun Apr 17 01:25:58 CST 2022, time=2022-04-17, status=1, ipAttribution=)]
    2022-04-17 jiyangfei
  5. [GetPortalCommentsPageByObjectIdResponse(id=1649513, encodeId=929d1649513d4, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Fri Nov 18 01:25:58 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729504, encodeId=c7131e29504e1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Aug 19 10:25:58 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219750, encodeId=ea381219e505e, content=nice,学习了 , beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3e76499938, createdName=ms6000001791212108, createdTime=Sun May 15 11:20:08 CST 2022, time=2022-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259565, encodeId=1eba12595658c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sun Apr 17 01:25:58 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365436, encodeId=c8f113654365a, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sun Apr 17 01:25:58 CST 2022, time=2022-04-17, status=1, ipAttribution=)]
    2022-04-17 mgqwxj

相关资讯

AJG:酒精性肝硬化患者戒酒对肝细胞癌风险的影响

酒精性脂肪肝是由于长期大量饮酒导致的肝脏疾病,是酒精性肝病中的一个分型。

AP&T: 慢性病毒性肝炎并发脂肪肝的肝细胞癌风险和死亡率会明显增加

肝细胞癌(HCC)是肝癌的主要组织学亚型,占原发性肝癌的90%,是全世界癌症相关死亡率的第三大常见原因。

European Radiology:Gd-EOB-DTPA增强MRI,实现HCC微血管浸润的无创评估!

微血管侵犯(MVI)是肝细胞癌(HCC)复发和影响预后的一个重要风险因素。对于有MVI的HCC患者,应扩大手术切除和射频消融的边缘范围,同时也应考虑将肝移植纳入替代治疗方法之一。

European Radiology:对于不同机构、不同机器、不同场强下进行的钆塞酸二钠增强MRI,是否仍可反应肝脏增强与肝功能的相关性?

钆塞酸二钠是一种肝细胞特异性对比剂,显示出选择性的肝细胞摄取,并在注射后约20分钟达到峰值(肝胆期)。

European Radiology:深卷积神经网络在预测HCC患者术前微血管浸润和临床预后方面的价值

肝细胞肝癌(HCC)的根治性切除术是早期HCC患者的第一选择。然而,术后2年的复发率很高,达到50%。

European Radiology:因为这一征象,我们改良了LI-RADS!

肝脏成像报告和数据系统(LI-RADS)是一个综合评估系统,主要目的是规范成像结果的词汇、解释和报告,以提高影像科内部与各科室之间高危肝细胞癌(HCC)诊断相关的解析及交流。